Sequenom (SQNM) has risen sharply, recording gains of 171.78% in the past 4 weeks. However, the stock has corrected -1.27% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 170.74% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Sequenom Inc. is up 122.86% in the last 3-month period. Year-to-Date the stock performance stands at 42.68%. The stock has recorded a 20-day Moving Average of 9.42% and the 50-Day Moving Average is 61.36%.
Sequenom (NASDAQ:SQNM): The stock opened at $2.36 on Friday but the bulls could not build on the opening and the stock topped out at $2.37 for the day. The stock traded down to $2.34 during the day, due to lack of any buying support eventually closed down at $2.34 with a loss of -0.85% for the day. The stock had closed at $2.36 on the previous day. The total traded volume was 3,031,246 shares.
Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.